Gene-edited cell therapy for sickle cell disease: what happens years later?
NCT ID NCT06155500
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This study follows 4 people with sickle cell disease who already received a gene-edited cell therapy called OTQ923. Researchers will check for delayed side effects, such as new cancers or blood disorders, and measure how long the therapy's benefits last. The goal is to understand the long-term safety and effectiveness of this one-time treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
St Jude Childrens Research Hospital
Memphis, Tennessee, 38105, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.